2023 Best of Lung Conference
Learners' Notification

Acknowledgement of Financial Commercial Support

No financial commercial support was received for this educational activity.

​

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

 

Satisfactory Completion

Learners must complete an evaluation form to receive a certificate of completion. Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

​

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferences. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

​

Physicians

Amedco LLC designates this live activity for a maximum of 4.5 AMA PRA Category 1 CreditsTM for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

​

Pharmacists

Amedco LLC designates this activity for a maximum of 4.5 knowledge-based CPE contact hours. 

​

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.

​

Nurses

Amedco LLC designates this activity for a maximum of 4.5 ANCC contact hours.

​

​

Objectives - After Attending This Program You Should Be Able To

1. Describe current and evolving management strategies for patients with localized and locally advanced lung cancer.

2. Identify best practices in biomarker testing and the utilization of biomarkers to drive treatment decisions for patients with lung cancer.

3. Explain the application of targeted therapy and immunotherapy in the treatment of NSCLC. Outline the clinical trial data on the use of

​

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1-6.2, 6.5) All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.